Nycomed releases lung agent in Europe
NeoSpect, a product for noninvasive diagnosis of suspected lung cancer, has entered the European market. The nuclear medicine product has been on the U.S. market since 1999 under the trade name NeoTect, which is being comarketed by Nycomed Amersham and
NeoSpect, a product for noninvasive diagnosis of suspected lung cancer, has entered the European market. The nuclear medicine product has been on the U.S. market since 1999 under the trade name NeoTect, which is being comarketed by Nycomed Amersham and Berlex. Developed and marketed by Nycomed Amersham Imaging, the agent binds selectively to the somatostatin receptor, which is overexpressed by malignant tumors in the lung. Current diagnostic methods typically uncover lung cancer only in advanced stages, offering little hope of recovery to the patient. NeoSpect has a high sensitivity for this type of cancer, raising prospects for early detection, according to the company. The high specificity may allow physicians to forego biopsy, otherwise required for a definitive diagnosis.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
